Full set of capabilities in Biotechnology
In 2007 Gedeon Richter together with Helm AG founded Richter-Helm Biologics Joint venture (JV) in Germany. The JV embraces state-of-the-art facilities specialised in
microbial cell fermentation technologies: FDA and EMA approved R&D laboratories in Hamburg, cGMP pilot plant capacities in Hannover, and FDA and EMA approved drug substance manufacturing plant in Bovenau.
Gedeon Richter also has significant capacities in
mammalian cell fermentation based technologies. In 2007 the first mammalian cell development R&D laboratories and a cGMP pilot plant were established in the Company's Budapest site. In 2008 Richter launched a green-field investment to build a plant in Debrecen in order to create the conditions for the manufacturing of mammalian cell products at commercial scale. The drug substance and fill-and-finish manufacturing plants were put into service in 2012.
Thanks to these investments too, Gedeon Richter's activities in biotechnology encompass the
full in-house value chain, ranging from research and development through manufacturing to commercialization in key geographical areas.
Current biotechnology portfolio
|
Product |
Indication |
Status |
| BEMFOLA (biosimilar r-hFSH) | Infertility | Richter acquired the product in 2016, marketed in more than 30 countries |
| TERROSA (biosimilar teriparatide) | Osteoporosis | Launched in Europe |
| Denosumab | Osteoporosis, oncology | Preclinical stage development |
| Tocilizumab |
Rheumatoid arthritis | Clinical stage development |
Further 3 biosimilar projects in early stage development
Partnering with us
The Company's Biotechnology Business Unit continuously seeks new partnerships in order to:
-
Leverage R&D, manufacturing and commercialization skills via in-licensing and co-development & co-commercialization in Europe, CIS and Latin America. Our areas of interest are:
- Osteoporosis
- Rheumatology
- Women's Healthcare
- Oncology
-
Secure co-development and commercialization (out-licensing) agreements for Gedeon Richter's biosimilar portfolio in the following geographic areas:
- USA & Canada
- Asia
- Australia and New Zealand
- MENA, Africa
Contact us
With your biotechnology inquiries you can reach us at the following e-mail addresses and phone numbers:
Dr. Johanna Knospe
Head of Biotechnology Business Development Department
E-mail: knospej@richter.hu
Office phone: +36-1-431-4928
Ivan Jako
Senior Partner Manager, Biotechnology Business Development Department
E-mail: jakoi@richter.hu
Office phone: +36-1-889-4799
Please send all your
non-biotechnology inquiries to the following email address:
license@richter.hu
